Rhoptry antigens as Toxoplasma gondii vaccine target

Masoud Foroutan; Fatemeh Ghaffarifar; Zohreh Sharifi; Abdolhosein Dalimi; Ogholniaz Jorjani

추천

검색

자료유형: 학술저널

저자정보: Masoud Foroutan (Tarbiat Modares University) Fatemeh Ghaffarifar (Tarbiat Modares University) Zohreh Sharifi (High Institute for Research and Education in Transfusion Medicine) Abdolhosein Dalimi (Tarbiat Modares University) Ogholniaz Jorjani (Golestan University of Medical Sciences)

저널정보: 대한백신학회 Clinical and Experimental Vaccine Research Clinical and Experimental Vaccine Research Vol.8 No.1

발행연도: 2019.1

수록면: 4 - 26 (23page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Toxoplasmosis is a cosmopolitan zoonotic infection, caused by a unicellular protozoan parasite known as Toxoplasma gondii that belongs to the phylum Apicomplexa. It is estimated that over one-third of the world’s population has been exposed and are latently infected with the parasite. In humans, toxoplasmosis is predominantly asymptomatic in immunocompetent persons, while among immunocompromised individuals may be cause severe and progressive complications with poor prognosis. Moreover, seronegative pregnant mothers are other risk groups for acquiring the infection. The life cycle of T. gondii is very complex, indicating the presence of a plurality of antigenic epitopes. Despite of great advances, recognize and construct novel vaccines for prevent and control of toxoplasmosis in both humans and animals is still remains a great challenge for researchers to select potential protein sequences as the ideal antigens. Notably, in several past years, constant efforts of researchers have made considerable advances to elucidate the different aspects of the cell and molecular biology of T. gondii mainly on microneme antigens, dense granule antigens, surface antigens, and rhoptry proteins (ROP). These attempts thereby provided great impetus to the present focus on vaccine development, according to the defined subcellular components of the parasite. Although, currently there is no commercial vaccine for use in humans. Among the main identified T. gondii antigens, ROPs appear as a putative vaccine candidate that are vital for invasion procedure as well as survival within host cells. Overall, it is estimated that they occupy about 1%-30% of the total parasite cell volume. In this review, we have summarized the recent progress of ROPbased vaccine development through various strategies from DNA vaccines, epitope or multi epitope-based vaccines, recombinant protein vaccines to vaccines based on live-attenuated vectors and prime-boost strategies in different mouse models.

#Toxoplasma gondii #Mice #Vaccines #Immunization #Adjuvant

참고문헌 (56)

참고문헌 신청

Chen G / 2001 / Construction of a recombinant plasmid harbouring the rhoptry protein 1 gene of Toxoplasma gondii and preliminary observations on DNA immunity / Chin Med J(Engl) 114:837~840

Guo H / 2001 / Immunity induced by DNA vaccine of plasmid encoding the rhoptry protein 1 gene combined with the genetic adjuvant of pcIFN-gamma against Toxoplasma gondii in mice / Chin Med J(Engl) 114:317~320

Quan JH / 2012 / Induction of protective immune responses by a multiantigenic DNA vaccine encoding GRA7 and ROP1 of Toxoplasma gondii / Clin Vaccine Immunol 19:666~674

Eslamirad Z / 2012 / Induction of protective immunity against toxoplasmosis in mice by immunization with a plasmid encoding Toxoplama gondii ROP1 gene / Afr J Biotechnol 11:8735~8741

Sonaimuthu P / 2016 / Induction of potective Immunity against txoplasmosis in BALB/c mce vccinated with Toxoplasma gondii roptry-1 / Front Microbiol 7:808

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!